Disease Category

Second-Generation Smallpox Vaccine: Modified Vaccinia Ankara (MVA)

NIAID recognized the need for a safer smallpox vaccine than Dryvax and ACAM2000 that could be used to protect patients with weakened immune systems, like those with HIV or cancer. A second-generation vaccine using Modified Vaccinia Ankara (MVA)-a highly weakened vaccinia virus that does not replicate well in humans is being developed by Bavarian Nordic.

National and Regional Biocontainment Research Facilities

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.  

Diagnostics Development Services

NIAID’s Diagnostics Development Services program offers reagents, platform testing, and planning and design support to accelerate product development of in vitro diagnostics (IVD) for infectious diseases, from research feasibility through clinical validation.

Heather Hickman, Ph.D.

Education:

Ph.D., University of Oklahoma

Photo of Heather Hickman, Ph.D.

Bernard Moss, M.D., Ph.D.

Education:

Ph.D., Massachusetts Institute of Technology

M.D., New York University School of Medicine

Photo of Bernard Moss, M.D., Ph.D.

Bioinformatics Resource Centers (BRCs) for Infectious Diseases

The NIAID-funded Bioinformatics Resource Centers provide data-driven, production-level, sustainable computational platforms to enable sharing and access to data, portable computational tools, and standards that support interoperability for the infectious diseases research community.

Systems Biology Consortium Resources

The Systems Biology Consortium for Infectious Diseases is a community of systems biologists who integrate experimental biology, computational tools and modeling across temporal and spatial scales to improve our understanding of infectious diseases. Through collaborative efforts, scientists test and validate hypotheses that drive innovation and discovery. The Consortium seeks to develop strategies that predict and alleviate disease severity and ultimately provide solutions to the world's most important health challenges.

Therapeutic Development Services

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

Vaccine and Treatment Evaluation Units (VTEUs) Services

The Vaccine and Treatment Evaluation Units (VTEUs), supported by the Division of Microbiology and Infectious Diseases (DMID) since the 1960s, provide a ready resource for the conduct of clinical trials to evaluate promising vaccines, treatments, and diagnostics for infectious diseases. The sites are part of DMID's Infectious Diseases Clinical Research Consortium (IDCRC).

Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID)—Resources

The Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID) provide the research community with: 3-D protein structures and protein-ligand complexes; Sequence-verified clones and peptides; Services that deliver requested 3-D structure determination; and Molecular screening of proteins in complex with inhibitors, cofactors and substrate analogs